BTD from the FDA very soonThe data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon.
Dr. Vera Madzarevic Director Clinical Development & Quality Assurance, Theralase®